Erica Rossitto, SVP and Chief Nurse Executive of HCA Healthcare, Inc., filed a Form 4 on November 10, 2026, disclosing a series of transactions in HCA common stock between November 6 and November 10, 2026.

Key Highlights

  • SAR exercise (first tranche): Rossitto exercised 8,080 stock appreciation rights at a conversion price of $81.96 on November 6, 2026, acquiring 8,080 shares of common stock.
  • SAR exercise (second tranche): She also exercised 5,040 stock appreciation rights at a conversion price of $101.16 on November 6, 2026, acquiring 5,040 shares.
  • Tax withholding disposition: 6,601 shares were disposed of on November 6, 2026, at $494.99 per share via transaction code F, reducing her direct holdings to 16,926 shares.
  • Open-market sale: On November 10, 2026, Rossitto sold 3,500 shares at $505.8101 per share.
  • Resulting ownership: Following all reported transactions, Rossitto directly held 13,426 shares of common stock.
  • Derivative position reduced to zero: Both SAR tranches were fully exercised, leaving Rossitto with 0 stock appreciation rights beneficially owned after the transactions.

Rossitto's November 2026 SAR Exercises and Share Transactions at HCA Healthcare

According to the filing, Erica Rossitto, identified as SVP and Chief Nurse Executive of HCA Healthcare, Inc. (NYSE:HCA), reported four transactions across two dates. On November 6, 2026, she exercised two separate tranches of stock appreciation rights. The first tranche covered 8,080 rights with a conversion price of $81.96, described in the filing as having vested in four equal annual installments beginning February 1, 2018. The second tranche covered 5,040 rights with a conversion price of $101.16, described as having vested in four equal annual installments beginning January 31, 2019. Both exercises carried a derivative security price of $0.00, as stated in the filing.

Also on November 6, 2026, the filing reports a disposition of 6,601 shares coded "F" at $494.99 per share, a transaction type commonly associated with shares withheld for tax obligations, though the filing does not use that characterization explicitly. That disposal brought her directly held common stock to 16,926 shares. On November 10, 2026, the filing records a sale coded "S" of 3,500 shares at a price of $505.8101, reducing her direct beneficial ownership to 13,426 shares. All positions are reported as directly owned. The Form 4 was signed by Kevin A. Ball as attorney-in-fact on November 10, 2026.

Following the reported transactions, the filing states that Rossitto beneficially owns zero stock appreciation rights, as both SAR tranches were fully exercised. Her remaining directly held common stock position stands at 13,426 shares, according to the disclosure.

What Was Disclosed

The filing disclosed the exercise of two stock appreciation right tranches totaling 13,120 rights, a disposition of 6,601 shares, and an open-market sale of 3,500 shares by Erica Rossitto of HCA Healthcare, Inc. between November 6 and November 10, 2026.